Implandata Ophthalmic Products’ implantable sensor directly measures IOP, but the device has not yet been approved for marketing. A pilot study in patients undergoing cataract surgery showed no narrowing of the anterior chamber and no device-related severe adverse events, but the size of the implant caused pupil distortion and other problems. A smaller iteration appears to have addressed the issues, said CEO Max Ostermeier, MD, and more detailed data will be discussed at the World Glaucoma Congress 2015 in June.
“This device allows you to take IOP readings anytime,” added Dr. Ostermeier. “It allows the physician to monitor the patient long term, and it allows the patient to monitor their own IOP, which empowers and involves them in treatment. Long-term, continuous monitoring is the way treatment will be guided and assessed.”
Sensimed has a CE-marked device, Triggerfish, which uses a contact lens sensor to measure changes in ocular volume.
“We see 24-hour IOP monitoring as a continuum of care,” said Sensimed CEO David Bailey. “The contact lens solution is minimally invasive screening and treatment management tool that is applicable to a very broad population. The implant is a targeted solution for a select population. The two together will benefit the entire spectrum of glaucoma treatment.”
Triggerfish uses a circular strain gauge to measure dimensional changes in the eye. Changes are transmitted wirelessly to a receiver that can be fitted to the face for sleeping or into eyeglasses for daytime use.
There is a strong correlation between changes in ocular volume and IOP, but the correlation has not yet been mapped, Bailey said. The company is using a data-registry, user groups and an advisory board to better define the clinical utility of ocular volume changes.